ヒトパピローマウイルス(HPV)関連がん(Human papillomavirus (HPV) Associated Cancer):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2014
◆商品コード:GMDHC5686IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるヒトパピローマウイルス(HPV)関連がん(Human papillomavirus (HPV) Associated Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・ヒトパピローマウイルス(HPV)関連がん(Human papillomavirus (HPV) Associated Cancer)の概要
・ヒトパピローマウイルス(HPV)関連がん(Human papillomavirus (HPV) Associated Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・ヒトパピローマウイルス(HPV)関連がん(Human papillomavirus (HPV) Associated Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・ヒトパピローマウイルス(HPV)関連がん(Human papillomavirus (HPV) Associated Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・ヒトパピローマウイルス(HPV)関連がん(Human papillomavirus (HPV) Associated Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Human papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Human papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2014’, provides an overview of the Human papillomavirus (HPV) Associated Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Human papillomavirus (HPV) Associated Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Human papillomavirus (HPV) Associated Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Human papillomavirus (HPV) Associated Cancer – Overview 11
Pipeline Products for Human papillomavirus (HPV) Associated Cancer – Comparative Analysis 12
Human papillomavirus (HPV) Associated Cancer – Therapeutics under Development by Companies 13
Human papillomavirus (HPV) Associated Cancer – Therapeutics under Investigation by Universities/Institutes 15
Human papillomavirus (HPV) Associated Cancer – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Human papillomavirus (HPV) Associated Cancer – Products under Development by Companies 19
Human papillomavirus (HPV) Associated Cancer – Products under Investigation by Universities/Institutes 21
Human papillomavirus (HPV) Associated Cancer – Companies Involved in Therapeutics Development 22
3SBio Inc. 22
Abivax 23
Antigen Express, Inc. 24
Bionor Pharma ASA 25
Cancer Therapeutics CRC Pty Ltd 26
Etubics Corporation 27
EyeGene, Inc. 28
Formune S.L. 29
Genexine, Inc. 30
Gliknik, Inc. 31
iBio, Inc. 32
Inovio Pharmaceuticals, Inc. 33
MedImmune, LLC 34
Merck & Co., Inc. 35
Onconova Therapeutics, Inc. 36
Prima BioMed Ltd. 37
Sirnaomics, Inc. 38
THERAVECTYS SA 39
Transgene SA 40
Vaccibody AS 41
ViroStatics, srl 42
Human papillomavirus (HPV) Associated Cancer – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
ABX-318 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AEH-10p – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Antibodies to Target E6 for HPV Associated Cancer – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Antibodies to Target E7 for HPV Associated Cancer – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cell Therapy to Target (HPV) E6 Protein for Papillomavirus Associated Cancers – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
durvalumab + tremelimumab – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
EDA-HPVE7 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
EG-HPV – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Gene Therapy for Papillomavirus Associated Cervical Carcinoma – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GL-0810 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
GX-188E – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
HPV Vaccine – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
human papillomavirus vaccine – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
human papillomavirus vaccine – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
human papillomavirus vaccine – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
INO-3106 – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
INO-3112 – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
P16-37-63 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
rigosertib sodium – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SSS-08 – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
STP-909 – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
STP-911 – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Subunit Vaccine for Cervical Cancer – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TG-4001 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
V-503 – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Vacc-HPV – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Vaccine for HPV Associated Cancer – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Vaccine for HPV Associated Cancers – Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Vaccine for HPV Associated Cancers – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Vaccine for HPV Associated Skin Cancer – Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Vaccine for HPV-Head and Neck Cancer – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
VB-1016 – Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Human papillomavirus (HPV) Associated Cancer – Recent Pipeline Updates 97
Human papillomavirus (HPV) Associated Cancer – Dormant Projects 105
Human papillomavirus (HPV) Associated Cancer – Product Development Milestones 106
Featured News & Press Releases 106
Mar 05, 2014: Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza 106
Nov 04, 2013: Merck’s Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study 106
Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine 108
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 110
Disclaimer 110

[List of Tables]
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H2 2014 11
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2014 21
Human papillomavirus (HPV) Associated Cancer - Pipeline by 3SBio Inc., H2 2014 22
Human papillomavirus (HPV) Associated Cancer - Pipeline by Abivax, H2 2014 23
Human papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H2 2014 24
Human papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H2 2014 25
Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2014 26
Human papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H2 2014 27
Human papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H2 2014 28
Human papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H2 2014 29
Human papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H2 2014 30
Human papillomavirus (HPV) Associated Cancer - Pipeline by Gliknik, Inc., H2 2014 31
Human papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H2 2014 32
Human papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 33
Human papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H2 2014 34
Human papillomavirus (HPV) Associated Cancer - Pipeline by Merck & Co., Inc., H2 2014 35
Human papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H2 2014 36
Human papillomavirus (HPV) Associated Cancer - Pipeline by Prima BioMed Ltd., H2 2014 37
Human papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H2 2014 38
Human papillomavirus (HPV) Associated Cancer - Pipeline by THERAVECTYS SA, H2 2014 39
Human papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H2 2014 40
Human papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H2 2014 41
Human papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics, srl, H2 2014 42
Assessment by Monotherapy Products, H2 2014 43
Assessment by Combination Products, H2 2014 44
Number of Products by Stage and Target, H2 2014 46
Number of Products by Stage and Mechanism of Action, H2 2014 48
Number of Products by Stage and Route of Administration, H2 2014 50
Number of Products by Stage and Molecule Type, H2 2014 52
Human papillomavirus (HPV) Associated Cancer Therapeutics - Recent Pipeline Updates, H2 2014 97
Human papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2014 105

[List of Figures]
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H2 2014 11
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Products, H2 2014 18
Assessment by Monotherapy Products, H2 2014 43
Number of Products by Top 10 Targets, H2 2014 45
Number of Products by Stage and Top 10 Targets, H2 2014 46
Number of Products by Top 10 Mechanism of Actions, H2 2014 47
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 48
Number of Products by Top 10 Routes of Administration, H2 2014 49
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 50
Number of Products by Top 10 Molecule Types, H2 2014 51
Number of Products by Stage and Top 10 Molecule Types, H2 2014 52

【掲載企業】

3SBio Inc.
Abivax
Antigen Express, Inc.
Bionor Pharma ASA
Cancer Therapeutics CRC Pty Ltd
Etubics Corporation
EyeGene, Inc.
Formune S.L.
Genexine, Inc.
Gliknik, Inc.
iBio, Inc.
Inovio Pharmaceuticals, Inc.
MedImmune, LLC
Merck & Co., Inc.
Onconova Therapeutics, Inc.
Prima BioMed Ltd.
Sirnaomics, Inc.
THERAVECTYS SA
Transgene SA
Vaccibody AS
ViroStatics, srl

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ヒトパピローマウイルス(HPV)関連がん(Human papillomavirus (HPV) Associated Cancer):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆